Info: Read More
  • 中药标准品生产商,产品定制服务
  • 七叶胆苷XVI

    Gypenoside XVII

    产品编号 CFN90193
    CAS编号 80321-69-3
    分子式 = 分子量 C48H82O18 = 947.16
    产品纯度 >=98%
    物理属性 White powder
    化合物类型 Triterpenoids
    植物来源 The roots of Panax notoginseng (Burk.) F.H.Chen.
    产品名称 产品编号 CAS编号 包装 QQ客服
    七叶胆苷XVI CFN90193 80321-69-3 10mg QQ客服:2932563308
    七叶胆苷XVI CFN90193 80321-69-3 20mg QQ客服:2932563308
    七叶胆苷XVI CFN90193 80321-69-3 50mg QQ客服:2932563308
    七叶胆苷XVI CFN90193 80321-69-3 100mg QQ客服:2932563308
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: 或

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.

    PMID: 30417089
  • Instytut Nawozów Sztucznych w Pu?awach (Poland)
  • Sapienza University of Rome (Italy)
  • Instituto Politécnico de Bragan?a (Portugal)
  • Pennsylvania State University (USA)
  • Kyushu University (Japan)
  • Semmelweis Unicersity (Hungary)
  • Lodz University of Technology (Poland)
  • Guangzhou Institutes of Biomedicine and Health (China)
  • Chungnam National University (Korea)
  • Seoul National University of Science and Technology (Korea)
  • University of Fribourg (Switzerland)
  • Universidade da Beira Interior (Germany)
  • Amity University (India)
  • University of Medicine and Pharmacy (Romania)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Biomedicines.2021, 9(8):954.
  • J Chromatogr B Analyt Technol Biomed Life Sci.2022, 1203:123307.
  • Biol Pharm Bull.2018, 41(11):1685-1693
  • Planta Med.2019, 85(4):347-355
  • bioRxiv2021, 458409.
  • Metabolites2022, 12(6),507.
  • Phytomedicine.2018, 41:62-66
  • Front Pharmacol.2018, 9:756
  • Korean J. Medicinal Crop Sci.2022, 30(2):124-133
  • Front Plant Sci.2021, 12:673337.
  • Metabolites.2020, 10(12):497.
  • Oncotarget.2015, 6(31):30831-49
  • Research J. Pharm. and Tech.2020, 13(7):3059-3064.
  • Environ Toxicol.2021, doi: 10.1002
  • Evid Based Complement Alternat Med.2018, 2018:3610494
  • Medicinal Chemistry Research 2021, 30:1117-1124.
  • Mol Pharm.2017, 14(9):3164-3177
  • Analytical Letters 2021, 54(4).
  • Molecules.2020, 25(15):3353.
  • Food Addit Contam Part A Chem Anal Control Expo Risk Assess.2020, 37(9):1437-1448.
  • Applied Biological Chemistry 2022, 65,5(2022).
  • Mol Immunol. 2016, 78:121-132
  • Process Biochemistry2019, 85:106-115
  • ...
  • 生物活性
    Description: Gypenoside XVII confers protection against Aβ25-35-induced neurotoxicity through estrogen receptor-dependent activation of PI3K/Akt pathways, inactivation of GSK-3β and activation of Nrf2/ARE/HO-1 pathways. Gypenoside XVII has protective effects to the cellular and rodent models of Alzheimer's disease by activating TFEB.
    Targets: Beta Amyloid | PI3K | Akt | GSK-3 | Nrf2 | HO-1 | ARE
    In vitro:
    Toxicol Appl Pharmacol. 2014 Aug 15;279(1):63-75.
    Attenuation of Aβ25-35-induced parallel autophagic and apoptotic cell death by gypenoside XVII through the estrogen receptor-dependent activation of Nrf2/ARE pathways.[Pubmed: 24726523]
    Amyloid-beta (Aβ) has a pivotal function in the pathogenesis of Alzheimer's disease.
    To investigate Aβ neurotoxicity, we used an in vitro model that involves Aβ25-35-induced cell death in the nerve growth factor-induced differentiation of PC12 cells. Aβ25-35 (20μM) treatment for 24h caused apoptotic cell death, as evidenced by significant cell viability reduction, LDH release, phosphatidylserine externalization, mitochondrial membrane potential disruption, cytochrome c release, caspase-3 activation, PARP cleavage, and DNA fragmentation in PC12 cells. Aβ25-35 treatment led to autophagic cell death, as evidenced by augmented GFP-LC3 puncta, conversion of LC3-I to LC3-II, and increased LC3-II/LC3-I ratio. Aβ25-35 treatment induced oxidative stress, as evidenced by intracellular ROS accumulation and increased production of mitochondrial superoxide, malondialdehyde, protein carbonyl, and 8-OHdG. Phytoestrogens have been proved to be protective against Aβ-induced neurotoxicity and regarded as relatively safe targets for AD drug development. Gypenoside XVII (GP-17) is a novel phytoestrogen isolated from Gynostemma pentaphyllum or Panax notoginseng. Pretreatment with Gypenoside XVII(10μM) for 12h increased estrogen response element reporter activity, activated PI3K/Akt pathways, inhibited GSK-3β, induced Nrf2 nuclear translocation, augmented antioxidant responsive element enhancer activity, upregulated heme oxygenase 1 (HO-1) expression and activity, and provided protective effects against Aβ25-35-induced neurotoxicity, including oxidative stress, apoptosis, and autophagic cell death. In conclusion, Gypenoside XVII conferred protection against Aβ25-35-induced neurotoxicity through estrogen receptor-dependent activation of PI3K/Akt pathways, inactivation of GSK-3β and activation of Nrf2/ARE/HO-1 pathways.
    This finding might provide novel insights into understanding the mechanism for neuroprotective effects of phytoestrogens or gypenosides.
    J Ginseng Res. 2012 Oct;36(4):418-24.
    Enzymatic Biotransformation of Ginsenoside Rb1 and Gypenoside XVII into Ginsenosides Rd and F2 by Recombinant β-glucosidase from Flavobacterium johnsoniae.[Pubmed: 23717145]

    This study focused on the enzymatic biotransformation of the major ginsenoside Rb1 into Rd for the mass production of minor ginsenosides using a novel recombinant β-glucosidase from Flavobacterium johnsoniae. The gene (bglF3) consisting of 2,235 bp (744 amino acid residues) was cloned and the recombinant enzyme overexpressed in Escherichia coli BL21(DE3) was characterized. This enzyme could transform ginsenoside Rb1 and gypenoside XVII to the ginsenosides Rd and F2, respectively. The glutathione S-transferase (GST) fused BglF3 was purified with GST-bind agarose resin and characterized. The kinetic parameters for β-glucosidase had apparent Km values of 0.91±0.02 and 2.84±0.05 mM and Vmax values of 5.75±0.12 and 0.71±0.01 μmol·min(-1)·mg of protein(-1) against p-nitrophenyl-β-D-glucopyranoside and Rb1, respectively. At optimal conditions of pH 6.0 and 37℃, BglF3 could only hydrolyze the outer glucose moiety of ginsenoside Rb1 and gypenoside XVII at the C-20 position of aglycon into ginsenosides Rd and F2, respectively.
    These results indicate that the recombinant BglF3 could be useful for the mass production of ginsenosides Rd and F2 in the pharmaceutical or cosmetic industry.
    In vivo:
    J Alzheimers Dis. 2016 Apr 5;52(3):1135-50.
    Gypenoside XVII Enhances Lysosome Biogenesis and Autophagy Flux and Accelerates Autophagic Clearance of Amyloid-β through TFEB Activation.[Pubmed: 27060963 ]
    A strategy for activating transcription factor EB (TFEB) to restore autophagy flux may provide neuroprotection against Alzheimer's disease. Our previous study reported that Gypenoside XVII (GP-17), which is a major saponin abundant in ginseng and Panax notoginseng, ameliorated amyloid-β (Aβ)25-35-induced apoptosis in PC12 cells by regulating autophagy.
    In the present study, we aimed to determine whether GP-17 has neuroprotective effects on PC12 cells expressing the Swedish mutant of APP695 (APP695swe) and APP/PS1 mice. We also investigated the underlying mechanism. We found that GP-17 could significantly increase Atg5 expression and the conversion of LC3-I to LC3-II in APP695 cells, which was associated with a reduction in p62 expression. GP-17 also elevated the number of LC3 puncta in APP695 cells transduced with pCMV-GFP-LC3. GP-17 promoted the autophagy-based elimination of AβPP, Aβ40, and Aβ42 in APP695swe cells and prevented the formation of Aβ plaques in the hippocampus and cortex of APP/PS1 mice. Furthermore, spatial learning and memory deficits were cured. Atg5 knockdown could abrogate the GP-17-mediated removal of AβPP, Aβ40, and Aβ42 in APP695swe cells. GP-17 upregulated LAMP-1, increased LysoTracker staining, and augmented LAMP-1/LC3-II co-localization. GP-17 could release TFEB from TFEB/14-3-3 complexes, which led to TFEB nuclear translocation and the induction of autophagy and lysosome biogenesis and resulted in the amelioration of autophagy flux. The knockdown of TFEB could abolish these effects of GP-17.
    In summary, these results demonstrated that GP-17 conferred protective effects to the cellular and rodent models of Alzheimer's disease by activating TFEB.
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 1.0558 mL 5.2789 mL 10.5579 mL 21.1158 mL 26.3947 mL
    5 mM 0.2112 mL 1.0558 mL 2.1116 mL 4.2232 mL 5.2789 mL
    10 mM 0.1056 mL 0.5279 mL 1.0558 mL 2.1116 mL 2.6395 mL
    50 mM 0.0211 mL 0.1056 mL 0.2112 mL 0.4223 mL 0.5279 mL
    100 mM 0.0106 mL 0.0528 mL 0.1056 mL 0.2112 mL 0.2639 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    Gynosaponin I; Gynosaponin I CFN96182 1207861-69-5 C42H72O12 = 769.0 5mg QQ客服:2932563308
    人参皂苷TN2; Gynosaponin TN2 CFN95331 77658-95-8 C42H72O13 = 785.0 5mg QQ客服:2159513211
    人参皂苷F2; Ginsenoside F2 CFN99755 62025-49-4 C42H72O13 = 785.01 20mg QQ客服:2932563308
    人参皂苷Rd2; Ginsenoside Rd2 (Quinquenoside L10) CFN95231 83480-64-2 C47H80O17 = 917.2 10mg QQ客服:1413575084
    七叶胆苷XVI; Gypenoside XVII CFN90193 80321-69-3 C48H82O18 = 947.16 20mg QQ客服:2932563308
    三七皂苷L13; Notoginsenoside L13 CFN95332 2485859-56-9 C47H78O17 = 915.1 5mg QQ客服:2932563308
    人参皂苷Rb2; Ginsenoside Rb2 CFN99965 11021-13-9 C53H90O22 = 1079.27 20mg QQ客服:3257982914
    人参皂苷Rb3; Ginsenoside Rb3 CFN99966 68406-26-8 C53H90O22 = 1079.27 20mg QQ客服:2159513211
    三七皂苷Fc; Notoginsenoside Fc CFN93283 88122-52-5 C58H98O26 = 1211.4 20mg QQ客服:1148253675
    人参皂苷Rb1; Ginsenoside Rb1 CFN99964 41753-43-9 C54H92O23 = 1109.29 20mg QQ客服:2932563308





    在线QQ: 1413575084


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产